Technology

Side CAR-T® delivery system

Lupagen avoids the cost & complexity of cell therapy and the safety & clinical challenges of viral-based gene therapy by a simple patient-connected gene delivery procedure done at the bedside.

Our Side CAR-T® delivery system, a first-in-class bedside system enables gene delivery directly to target cells in a highly-controlled and safe environment before reinfusing therapies to the patient in a simple out-patient procedure, resulting in significantly lower treatment burden and cost.

Picture3_edited.png

“Best of Breed” Nanoparticle Gene Delivery Platform

Lupagen is developing nanoparticle-based gene therapies internally and in partnership with select biopharma companies that can be delivered using our Side CAR-T® delivery system and accommodate a wide range of payloads & gene editing systems resulting in safer, more effective gene therapy eliminating cost and safety concerns from viral transduction or electroporation transfection. 

Platform payload.png

Nanoparticle platforms, widely used to deliver RNA and DNA, can be delivered elegantly to targeted peripheral blood mononuclear cell populations to generate cell & gene therapies addressing oncology, respiratory/allergy, autoimmune and rare disease indications.

Therapies and Indications.png

Lupagen’s flexible platform agnostic development approach combined with our proprietary bedside delivery system results in:

  • Broader array of targets and indications that can be developed

  • Ability to leverage a wide range of nanoparticles systems (lipid, polymer, coated virus)

  • SAFER and MORE EFFECTIVE targeted delivery of nanoparticles  than can be achieved in-vivo by avoiding current systemic toxicity and dosing challenges

LNP Graphic.png

© 2021 by Lupagen